Eris Lifesciences · NSE: ERIS · BSE: 540596
Q3 FY25 results · Oct–Dec 2024
Eris Lifesciences reported revenue from operations of ₹727.45 crore (up 49.6% from Q3 FY24) and net profit of ₹86.93 crore (down 14.3% from Q3 FY24) for Q3 FY25 (Oct–Dec 2024), on a consolidated basis.
| Item | Q3 FY25 | Q3 FY24 | YoY | Q2 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 727.45 | 486.30 | +49.6% | 738.95 | −1.6% |
| Other income | 4.22 | 4.20 | +0.5% | 6.77 | −37.7% |
| Total income | 731.67 | 490.49 | +49.2% | 745.72 | −1.9% |
| Profit before tax | 116.16 | 115.87 | +0.3% | 129.11 | −10.0% |
| Net profit for the period | 86.93 | 101.46 | −14.3% | 96.35 | −9.8% |
| Attributable to shareholders of the company | 83.62 | 102.74 | −18.6% | 91.59 | −8.7% |
| EPS, basic (₹) | 6.15 | 7.55 | −18.5% | 6.73 | −8.6% |
| Net margin (%) | 11.9 | 20.9 | 13.0 |
| Item | Q3 FY25 | Q3 FY24 | YoY | Q2 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 399.73 | 324.41 | +23.2% | 428.75 | −6.8% |
| Other income | 7.79 | 3.43 | +126.9% | 13.62 | −42.8% |
| Total income | 407.52 | 327.85 | +24.3% | 442.37 | −7.9% |
| Profit before tax | 6.03 | 34.64 | −82.6% | 46.02 | −86.9% |
| Net profit for the period | 1.78 | 31.66 | −94.4% | 28.10 | −93.7% |
| EPS, basic (₹) | 0.13 | 2.33 | −94.4% | 2.06 | −93.6% |
| Net margin (%) | 0.4 | 9.8 | 6.6 |
Consolidated
- Filed with BSE
- 05 Feb 2025, 12:04 IST
- Board meeting
- 04 Feb 2025
- Period
- 01 Oct 2024 to 31 Dec 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 05 Feb 2025, 12:04 IST
- Board meeting
- 04 Feb 2025
- Period
- 01 Oct 2024 to 31 Dec 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE